糖尿病合并新型冠状病毒感染血糖控制状况对预后影响的研究现状

丛日平; 张雨健; 高斌雪; 张建波; 徐露佳; 刁瑛丽; 王伟; 唐宽晓

doi:10.16766/j.cnki.issn.1674-4152.003473

糖尿病合并新型冠状病毒感染血糖控制状况对预后影响的研究现状

doi: 10.16766/j.cnki.issn.1674-4152.003473

1.
山东大学齐鲁医院全科医学科，山东济南 250012
2.
山东大学齐鲁医院急诊科

详细信息

通讯作者:
唐宽晓，E-mail：tangkx_ql@hotmail.com

中图分类号: R587.1 R511
计量
- 文章访问数: 74
- HTML全文浏览量: 28
- PDF下载量: 4
- 被引次数: 0
出版历程
- 收稿日期: 2024-01-21
- 网络出版日期: 2024-05-29

Research progress of the effect of glycemic control on the prognosis of diabetes with corona virus disease 2019

1.
Department of General Practice, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China

摘要

摘要: 新型冠状病毒感染(corona virus disease 2019, COVID-19)是由严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)引起的发病率高、传染性强、病情变化快的急性传染性疾病。糖尿病[主要是2型糖尿病(type 2 diabetes mellitus, T2DM)]合并感染COVID-19具有控制困难、并发症多、危重率高、致死率高等特点，其重要原因之一是血糖波动性较大。目前尚无公认的血糖目标范围时间(time in range, TIR)，TIR与患者的预后及转归密切相关。血糖变异性参数是预测危重症患者死亡的独立影响因素，监测评估血糖波动是血糖精细化管理的重要内容。本文就T2DM合并COVID-19患者血糖控制状况对预后影响的国内外研究现状进行综述，主要内容包括T2DM合并COVID-19的流行病学现状、主要病理生理机制(如炎症因子风暴、血管紧张素转化酶2表达异常等)、血糖控制目标、住院及出院患者综合管理等，旨在为优化诊治策略、改善预后、降低并发症发生率及病死率等提供理论参考依据。
- 新型冠状病毒感染 /
- 糖尿病 /
- 血糖波动
Abstract: Corona virus disease 2019 (COVID-19) is an acute infectious disease caused by severe acute respiratory syndrome coronavirus 2 with high incidence, strong infectivity and rapid state change. The characteristics of type 2 diabetes mellitus (T2DM) with COVID-19 are uncontrollable, many complications, high critical rate and mortality. Blood glucose variability is one of the main reasons. Currently, there is no accepted time in range (TIR), and TIR is closely associated with prognosis. Glucose variability parameters are independent risk factors for predicting mortality in critical patients. The monitoring of glucose variability is important to realize the fine management of blood glucose. This article reviews the research progress of the effect of glycemic control on the prognosis of T2DM with COVID-19. The main contents include the epidemiological status, major pathophysiological mechanisms (e.g., cytokine release syndrome, abnormal expression of angiotensin-converting enzyme 2, etc.), glycemic control goals, and scientific management of patients. This review provides a theoretical reference for optimizing the diagnosis and treatment strategy, improving the prognosis, and reducing the incidence of complications and mortality.
- Corona virus disease 2019 /
- Diabetes mellitus /
- Blood glucose fluctuation

HTML全文

参考文献(42)

[1]	SHAH K, TIWASKAR M, CHAWLA P, et al. Hypoglycemia at the time of Covid-19 pandemic[J]. Diabetes Metab Syndr, 2020, 14(5): 1143-1146. doi: 10.1016/j.dsx.2020.07.003
[2]	SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119. DOI: 10.1016/j.diabres.2021.109119.
[3]	SINGH A K, KHUNTI K. COVID-19 and diabetes[J]. Annu Rev Med, 2022, 73: 129-147. doi: 10.1146/annurev-med-042220-011857
[4]	HUANG C L, WANG Y M, LI X W, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5
[5]	GUAN W J, NI Z Y, HU Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708-1720. doi: 10.1056/NEJMoa2002032
[6]	CHEN N S, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513. doi: 10.1016/S0140-6736(20)30211-7
[7]	The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020[J]. China CDC Wkly, 2020, 2(8): 113-122. doi: 10.46234/ccdcw2020.032
[8]	CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States, February 12-March 28, 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(13): 382-386. doi: 10.15585/mmwr.mm6913e2
[9]	DOCHERTY A B, HARRISON E M, GREEN C A, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study[J]. BMJ, 2020, 369: m1985. DOI: 10.1136/bmj.m1985.
[10]	YANG J, ZHENG Y, GOU X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis[J]. Int J Infect Dis, 2020, 94: 91-95. doi: 10.1016/j.ijid.2020.03.017
[11]	HU Y, SUN J Z, DAI Z, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis[J]. J Clin Virol, 2020, 127: 104371. DOI: 10.1016/j.jcv.2020.104371.
[12]	JINDAL R, GUPTA M, KHAN F R, et al. Prevalence of co-morbidities and its association with mortality in Indian patients with COVID-19: a meta-analysis[J]. Indian J Anaesth, 2022, 66(6): 399-418. doi: 10.4103/ija.ija_845_21
[13]	ZHOU F, YU T, DU R H, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3
[14]	SEIGLIE J, PLATT J, CROMER S J, et al. Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19[J]. Diabetes Care, 2020, 43(12): 2938-2944. doi: 10.2337/dc20-1506
[15]	VANGOITSENHOVEN R, MARTENS P J, VAN NES F, et al. No evidence of increased hospitalization rate for COVID-19 in community-dwelling patients with type 1 diabetes[J]. Diabetes Care, 2020, 43(10): e118-e119. DOI: 10.2337/dc20-1246.
[16]	BARRON E, BAKHAI C, KAR P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study[J]. Lancet Diabetes Endo, 2020, 8(10): 813-822. doi: 10.1016/S2213-8587(20)30272-2
[17]	SINGH A K, GUPTA R, GHOSH A, et al. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations[J]. Diabetes Metab Syndr, 2020, 14(4): 303-310. doi: 10.1016/j.dsx.2020.04.004
[18]	LIU F, LI L, XU M D, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19[J]. J Clin Virol, 2020, 127: 104370. DOI: 10.1016/j.jcv.2020.104370.
[19]	ZHAO Y Y, XING H C. Influence of fasting plasma glucose level on admission of COVID-19 patients: a retrospective study[J]. J Diabetes Res, 2022, 2022: 7424748. DOI: 10.1155/2022/7424748.
[20]	MADDALONI E, BUZZETTI R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics[J]. Diabetes Metab Res Rev, 2020, 36(7): e33213321. DOI: 10.1002/dmrr.3321.
[21]	SAPUTRA G N R, YUDHAWATI R, FITRIAH M. Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: a cross-sectional study[J]. Ann Med Surg (Lond), 2022, 74: 103303. DOI: 10.1016/j.amsu.2022.103303.
[22]	FELDMAN E L, SAVELIEFF M G, HAYEK S S, et al. COVID-19 and Diabetes: a collision and collusion of two diseases[J]. Diabetes, 2020, 69(12): 2549-2565. doi: 10.2337/dbi20-0032
[23]	CERIELLO A, DE NIGRIS V, PRATTICHIZZO F. Why is hyperglycaemia worsening COVID-19 and its prognosis?[J]. Diabetes Obes Metab, 2020, 22(10): 1951-1952. doi: 10.1111/dom.14098
[24]	BRUFSKY A. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic[J]. J Med Virol, 2020, 92(7): 770-775. doi: 10.1002/jmv.25887
[25]	SANKRITYAYAN H, KALE A, SHARMA N, et al. Evidence for use or disuse of renin-angiotensin system modulators in patients having COVID-19 with an underlying cardiorenal disorder[J]. J Cardiovasc Pharmacol Ther, 2020, 25(4): 299-306. doi: 10.1177/1074248420921720
[26]	WILLIAMSON E J, WALKER A J, BHASKARAN K, et al. Factors associated with COVID-19-related death using OpenSAFELY[J]. Nature, 2020, 584(7821): 430-436. doi: 10.1038/s41586-020-2521-4
[27]	CAI Y L, SHI S B, YANG F, et al. Fasting blood glucose level is a predictor of mortality in patients with COVID-19 independent of diabetes history[J]. Diabetes Res Clin Pract, 2020, 169: 108437. DOI: 10.1016/j.diabres.2020.108437.
[28]	DUAN W W, LI L Y, LI X S, et al. Association of blood glucose level and prognosis of inpatients with coexistent diabetes and COVID-19[J]. Endocrine, 2022, 75(1): 1-9. doi: 10.1007/s12020-021-02923-7
[29]	ZHU B, JIN S W, WU L P, et al. J-shaped association between fasting blood glucose levels and COVID-19 severity in patients without diabetes[J]. Diabetes Res Clin Pract, 2020, 168: 108381. DOI: 10.1016/j.diabres.2020.108381.
[30]	CHEN L K, SUN W W, LIU Y L, et al. Association of early-phase in-hospital glycemic fluctuation with mortality in adult patients with coronavirus disease 2019[J]. Diabetes Care, 2021, 44(4): 865-873. doi: 10.2337/dc20-0780
[31]	BODE B, GARRETT V, MESSLER J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States[J]. J Diabetes Sci Technol, 2020, 14(4): 813-821. doi: 10.1177/1932296820924469
[32]	ZHU L H, SHE Z G, CHENG X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes[J]. Cell Metab, 2020, 31(6): 1068-1077.e3. doi: 10.1016/j.cmet.2020.04.021
[33]	师瑞, 冯磊, 唐灵通, 等. 糖尿病患者血糖波动评价指标研究进展[J]. 中华全科医学, 2022, 20(12): 2105-2109. doi: 10.16766/j.cnki.issn.1674-4152.002780?viewType=HTML SHI R, FENG L, TANG L T, et al. Research progress on evaluation indicators of blood glucose fluctuation in patients with diabetes[J]. Chinese Journal of General Practice, 2022, 20(12): 2105-2109. doi: 10.16766/j.cnki.issn.1674-4152.002780?viewType=HTML
[34]	KAPOOR R, TIMSINA L R, GUPTA N, et al. Maintaining blood glucose levels in range (70-150 mg/dL) is difficult in COVID-19 compared to non-COVID-19 ICU patients-a retrospective analysis[J]. J Clin Med, 2020, 9(11): 3635. DOI: 10.3390/jcm9113635.
[35]	SHEN Y, FAN X H, ZHANG L, et al. Thresholds of Glycemia and the outcomes of COVID-19 complicated with diabetes: a retrospective exploratory study using continuous glucose monitoring[J]. Diabetes Care, 2021, 44(4): 976-982. doi: 10.2337/dc20-1448
[36]	RAYMAN G, LUMB A, KENNON B, et al. Guidelines for the management of diabetes services and patients during the COVID-19 pandemic[J]. Diabet Med, 2020, 37(7): 1087-1089. doi: 10.1111/dme.14316
[37]	LI G D, HILGENFELD R, WHITLEY R, et al. Therapeutic strategies for COVID-19: progress and lessons learned[J]. Nat Rev Drug Discov, 2023, 22(6): 449-475. doi: 10.1038/s41573-023-00672-y
[38]	MONDA V M, VOCI C, STROLLO F, et al. Protective effects of home T2DM treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors against intensive care unit admission and mortality in the acute phase of the COVID-19 pandemic: a retrospective observational study in Italy[J]. Diabetes Ther, 2023, 14(12): 2127-2142. doi: 10.1007/s13300-023-01472-8
[39]	RAHIMI L, MALEK M, ISMAIL-BEIGI F, et al. Challenging issues in the management of cardiovascular risk factors in diabetes during the COVID-19 pandemic: a review of current literature[J]. Adv Ther, 2020, 37(8): 3450-3462. doi: 10.1007/s12325-020-01417-8
[40]	RECOVERY Collaborative Group, HORBY P, LIM W S, et al. Dexamethasone in hospitalized patients with COVID-19[J]. N Engl J Med, 2021, 384(8): 693-704. doi: 10.1056/NEJMoa2021436
[41]	AYOUBKHANI D, KHUNTI K, NAFILYAN V, et al. Post-covid syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study[J]. BMJ, 2021, 372: n693. DOI: 10.1136/bmj.n693.
[42]	MARFELLA R, D'ONOFRIO N, SARDU C, et al. Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: the CAVEAT study[J]. Diabetes Obes Metab, 2022, 24(1): 160-165. doi: 10.1111/dom.14547